Several interesting combinations of therapies with Calquence for patients with CLL
Calquence, acalabrutinib, is a specific inhibitor of Bruton tyrosine kinase and a very effective and well-tolerated drug in treating CLL. At this year’s ASH Congress, several studies of combination therapies were presented, showing, according to Matthew S. David, that acalabrutinib will be a part of the combinations in the future. In this MEDtalk, Matthew S. Davids from the Dana Faber Cancer Institute in Boston, USA, gives his perspective on the combinations with acalabrutinib.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.